CRISPR has crossed a turning point, evolving from an experimental tool into a platform delivering FDA-approved therapies and on-demand patient treatments that correct disease at its source. Brad Ringeisen, a former DARPA office director and leader at the Innovative Genomics Institute (IGI), has been at the center of that transition, helping guide CRISPR from early promise toward scalable clinical impact. Ringeisen discusses in this episode how he is collaborating with CRISPR pioneer and Nobel Prize winner Jennifer Doudna, PhD, at the IGI to address rare, complex, and underserved diseases, going beyond isolated successes. Accessibility, durability, and worldwide benefit, Ringeisen believes, will be the real indicators of CRISPR's success.

Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.